Research suggests that Epimedium and its primary bioactive compounds, icariin and icariside II, may support erectile function and broader male sexual health through several identified biological mechanisms, including inhibition of PDE5 (the same enzyme targeted by pharmaceutical erectile dysfunction drugs), enhancement of nitric oxide and cyclic GMP signaling, reduction of oxidative stress, and promotion of testosterone synthesis in Leydig cells. Studies indicate that these compounds have demonstrated meaningful effects on erectile function across multiple rat models, including those simulating diabetic, hypertensive, radiation-induced, and nerve-injury-related erectile dysfunction, with the supporting body of work including both experimental animal studies and narrative reviews drawing on traditional Chinese medicine and modern pharmacological research. However, a notable limitation of the current evidence base is that the overwhelming majority of studies are preclinical animal experiments, with a substantial absence of well-designed randomized controlled trials in humans, meaning it remains unclear how consistently or robustly these findings would translate to human sexual function outcomes. The overall direction of the available literature is supportive, but the lack of clinical trial data means that conclusions about efficacy in humans should be held cautiously until higher-quality human studies are conducted.
Citations from PubMed and preprint sources. Match score (0-100) reflects automated search ranking, not clinical appraisal.
| Title | Type | Year | Direction | Match |
|---|---|---|---|---|
| Effects of icariside II on improving erectile function in rats with streptozo... | Other | 2012 | Supports | 95 |
| Antioxidant icariside II combined with insulin restores erectile function in ... | Other | 2015 | Supports | 93 |
| Icariin improves erectile function in spontaneously hypertensive rats by down... | Other | 2025 | Supports | 92 |
| [Icariin improves erectile function in spontaneously hypertensive rats by up-... | Other | 2021 | Supports | 92 |
| A Novel Flavonoid Derivative of Icariside II (YS-10) Improves Erectile Dysfun... | Other | 2025 | Supports | 90 |
| A flavonoid derivative of icariside II (YS-10) improves erectile dysfunction ... | Other | 2022 | Supports | 90 |
| A novel flavonoid derivative of icariside II improves erectile dysfunction in... | Other | 2021 | Supports | 90 |
| Pharmacological effects and pharmacokinetic properties of icariin, the major ... | Review | 2015 | Supports | 88 |
| Rise of herbal and traditional medicine in erectile dysfunction management. | Review | 2011 | Supports | 88 |
| The genus Epimedium: an ethnopharmacological and phytochemical review. | Review | 2011 | Supports | 87 |
| Therapeutic Challenges of Diabetes Mellitus-Related Erectile Dysfunction and ... | Review | 2025 | Supports | 85 |
| Therapeutic effects of icariin and icariside II on diabetes mellitus and its ... | Review | 2024 | Supports | 85 |
| Icariin promotes mouse Leydig cell testosterone synthesis via the Esr1/Src/Ak... | Other | 2022 | Supports | 83 |
| Medicinal plants as a potential source of Phosphodiesterase-5 inhibitors: A r... | Review | 2021 | Supports | 82 |
| Chemotherapeutic Potential of Epimedium brevicornum Extract: The cGMP-Specifi... | Other | 2020 | Supports | 80 |
| An Analysis of Popular Online Erectile Dysfunction Supplements. | Systematic review | 2019 | Supports | 80 |
| Icariin inhibition of NLRP3 mediated Leydig cell pyroptosis and insulin resis... | Other | 2025 | Supports | 78 |
| Anti-Cancer Properties of the Naturally Occurring Aphrodisiacs: Icariin and I... | Review | 2016 | Supports | 75 |
| Advancements in the Biotransformation and Biosynthesis of the Primary Active ... | Review | 2023 | Supports | 72 |
| Horny Goat Weed. | Review | 2012 | Supports | 72 |
| Guhan Yangsheng Jing mitigates oxidative stress and ferroptosis to improve re... | Other | 2025 | Supports | 70 |